RecruitingPhase 3NCT05183646
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Studying Hereditary steroid-resistant nephrotic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dimerix Bioscience Pty Ltd
- Principal Investigator
- David FullerDimerix Bioscience Pty Ltd
- Intervention
- DMX-200(drug)
- Enrollment
- 286 target
- Eligibility
- 12-80 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- Amicis Research Centre, Northridge, California, United States
- Northridge Clinical Research Inc., Northridge, California, United States
- Kaiser Permanente, Oakland, California, United States
- University of California Davis Health System, Sacramento, California, United States
- Scripps Health, San Diego, California, United States
- Stanford Hospital and Clinic, Stanford, California, United States
- University of Colorado Anschutz Medical Campus, Denver, Colorado, United States
- Denver Nephrology Research Division, Denver, Colorado, United States
- South Florida Nephrology Group, P.A., Coral Springs, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05183646 on ClinicalTrials.govOther trials for Hereditary steroid-resistant nephrotic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06635720REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)The Hospital for Sick Children
- RECRUITINGNCT06334692Autoantibodies Against-nephrin in Idiopathic Nephrotic SyndromeMario Negri Institute for Pharmacological Research
- RECRUITINGNCT06162546ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and BiobankChristoph Aufricht
- RECRUITINGNCT01605266INSIGHT (Insight Into Nephrotic Syndrome)The Hospital for Sick Children
See all trials for Hereditary steroid-resistant nephrotic syndrome →